ID Biomedical To Decide On 2005 U.S. Flu Vaccine Production By Late January

Vancouver-based company will meet with FDA in January to determine whether it will be able to pursue accelerated licensure for Fluviral. The company has reached guaranteed U.S. purchase and distribution agreements with Henry Schein, AmerisourceBergen and McKesson potentially worth $2.5 bil. over 10 years.